BeiGene

BeiGene is a biotechnology company that develops and commercializes immunotherapeutics for the treatment of cancer. Read more

John V. Oyler's photo - Chairman & CEO of BeiGene

Chairman & CEO

John V. Oyler

CEO Approval Rating

90/100

Founded:

2010

Status:

PublicIndependent CompanyNASDAQBGNE

BEIGENE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Innovent Biologics is the top competitor of BeiGene. Innovent Biologics is headquartered in Suzhou, Jiangsu Province, and was founded in 2011. Innovent Biologics competes in the Pharmaceuticals field. Innovent Biologics generates 68% the revenue of BeiGene.

Sino Biological is perceived as one of BeiGene's biggest rivals. Sino Biological was founded in Beijing, Beijing Municipality} in 2007. Like BeiGene, Sino Biological also operates in the Biotechnology industry. Compared to BeiGene, Sino Biological generates $832.7M less revenue.

CARsgen is seen as one of BeiGene's top competitors. CARsgen is a Private company that was founded in Xuhui, Shanghai Municipality in 2014. Like BeiGene, CARsgen also works within the Biotechnology industry. CARsgen has 766 fewer employees vs. BeiGene.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is TESARO a competitor of BeiGene?

BeiGene Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$862.7M

BeiGene's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 219.9M. Over the last four quarters, BeiGene's revenue has grown by 823.1%. Specifically, in Q1 2021's revenue was $605.9M; in Q4 2020, it was $100.1M; in Q3 2020, it was $91.1M; in Q2 2020, BeiGene's revenue was $65.6M.

BeiGene Acquisitions

No recent acquisitions found related to BeiGene

BeiGene Funding History

Since BeiGene was founded in 2010, it has participated in 5 rounds of funding. In total BeiGene has raised $2.6B. BeiGene's last funding round was on Jul 2020 for a total of $2.1B

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Jul 2020
$2.1B
Secondary Offering
Nov 2016
$200M
-
IPO
Feb 2016
$158M
-
Private Equity Round
May 2015
$96.6M

Hillhouse Capital Group

Series A
Nov 2014
$75M

Since BeiGene was founded in 2010, it has participated in 5 rounds of funding. In total BeiGene has raised $2.6B. BeiGene's last funding round was on Jul 2020 for a total of $2.1B

BeiGene Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

BITT is a Boston-based biotechnology company that develops and commercializes novel cancer immunotherapy for autoimmunity and infectious disease.
$10M
Mar 16, 2021
Series A
-
Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells.
$27M
Jan 05, 2020
Equity
-

BeiGene News

June 11, 2021PMLiVE

BeiGene's reveals positive data for Brukinsa in head-to-head Imbruvica trial

Results presented at EHA2021 virtual congress showed an improved overall response rate for Brukinsa o... See more »
June 11, 2021Benzinga

BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica

BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukin... See more »
June 10, 2021BioPharma-Reporter

Shoreline Biosciences and BeiGene collaborate on genetically modified natural killer cell therapies

Shoreline Biosciences and BeiGene have announced an exclusive worldwide strategic collaboration to de... See more »
June 9, 2021Endpoints News

BeiGene dives in on natural killer cells with discovery pact for small biotech's stem cell-based platform

China's BeiGene has been busy on the oncology front in recent years, looking to keep up with the pack... See more »

BeiGene Press Releases

May 12, 2021Business Wire

BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160... See more »
May 6, 2021Business Wire

BeiGene Reports First Quarter 2021 Financial Results

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene reported recent business highlig... See more »
March 10, 2021Business Wire

BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Presentation of Clinic... See more »
January 7, 2021Business Wire

BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06... See more »
November 5, 2020Business Wire

BeiGene Announces Data on BRUKINSA (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA® (zanu... See more »
September 10, 2020Business Wire

BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene announced that the Company wi... See more »
August 6, 2020GlobeNewswire

BeiGene Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; H... See more »

BeiGene Videos

Social Media

BeiGene Headquarters

30 Science Park Road Zhong-Guan-Cun Life Science Park, Changping District

Beijing, Beijing Municipality102206

86-10-589-580-00

Driving Directions »

Trending Companies

BeiGene Summary

ABOUT

Overview

BeiGene is a biotechnology company that develops and commercializes immunotherapeutics for the treatment of cancer. BeiGene was founded in 2010. BeiGene's headquarters is located in Beijing, Beijing Municipality, CN 102206. It has raised 2.6B in 5 rou...

CEO

BeiGene's Chairman & CEO, John V. Oyler, currently has an approval rating of 90%. BeiGene's primary competitors are Innovent Biologics, Sino Biological & CARsgen.

Frequently Asked Questions about BeiGene

  1. When was BeiGene founded?

    BeiGene was founded in 2010
  2. Who is BeiGene's CEO?

    BeiGene's CEO is John V. Oyler
  3. How much revenue does BeiGene generate?

    BeiGene generates $862.7M in revenue
  4. How much funding does BeiGene have?

    BeiGene has historically raised $2.6B in funding
  5. Where is BeiGene's headquarters?

    BeiGene's headquarters is in Beijing Beijing Municipality, CN
  1. How many employees does BeiGene have?

    BeiGene has 876 employees
  2. What sector does BeiGene operate in?

    BeiGene is in Biotechnology, Medical Research & Laboratories
  3. Who are BeiGene's competitors?

    BeiGene's top competitors are Innovent Biologics, Sino Biological, CARsgen
  4. Who has BeiGene invested in?

    BeiGene's has invested in companies such as BITT, Leap Therapeutics